Niagen Bioscience targets 10-15% revenue growth for 2026 while expanding injectable product line
Source: SeekingAlpha
2026-03-04 19:12:50 ET
More on Niagen Bioscience
- Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
- Niagen Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market
- Niagen Bioscience GAAP EPS of $0.05 beats by $0.03, revenue of $33.84M beats by $2.14M
- Niagen Bioscience acquires core Nicotinamide Riboside patents
Read the full article on Seeking Alpha
For further details see:
Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line
Niagen Bioscience Inc.
NASDAQ: NAGE
NAGE Trading
0.76% G/L:
$5.275 Last:
233,712 Volume:
$5.12 Open:
NAGE Latest News
March 10, 2026 08:32:00 am
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud(TM), From Tru Niagen Powered by Patented Niagen®
NAGE Stock Data
$408,607,432
52,743,877
N/A
66
N/A
Biotechnology & Life Sciences
Healthcare
US
Los Angeles
